|
|
||||||||
From the Departments of Neurology (Drs. Christodoulou, Krupp, MacAllister, and Peyster, P. Melville, W.F. Scherl, and T. Morgan), Radiology (Drs. Liang, Huang, Roque, L. Li, Tudorica, X. Li, Roche, and Peyster), Psychology (Dr. Krupp), Computer Science (Dr. Liang), and Neurosurgery (Dr. Roque), State University of New York at Stony Brook.
Address correspondence and reprint requests to Dr. Christopher Christodoulou, Department of Neurology, State University of New York at Stony Brook, HSC T12-020, Stony Brook, NY 11794-8121; e-mail: christopher.christodoulou{at}sunysb.edu
Objective: To relate neuropsychological performance to measures of cerebral injury in persons with MS selected for cognitive impairment.
Methods: Participants were 37 individuals with relapsingremitting (59.5%) and secondary progressive (40.5%) MS. They were tested at baseline as part of a clinical trial to enhance cognition with an acetylcholinesterase inhibitor. Eligibility criteria included at least mild cognitive impairment on a verbal learning and memory task. A modified Brief Repeatable Battery of Neuropsychological Tests formed the core of the behavioral protocol. Neuroimaging measures were central (ventricular) cerebral atrophy, lesion volume, and ratios of N -acetyl aspartate (NAA) to both creatine and choline.
Results: A clear, consistent relation was found between cognitive and MR measures. Among neuroimaging measures, central atrophy displayed the highest correlations with cognition, accounting for approximately half the variance in overall cognitive performance. NAA ratios in right hemisphere sites displayed larger correlations than those on the left. Multiple regression models combining the MR measures accounted for well over half the variance in overall cognitive performance. The Symbol Digit Modalities Test was the neuropsychological task most strongly associated with the neuroimaging variables.
Conclusions: If a strong and stable association can be firmly established between cognitive and MR variables in appropriate subsets of MS patients, it might aid in the investigation of interventions to enhance cognition and modify the course of the disease.
This article has been cited by other articles:
![]() |
R. Benedict, J. Duquin, S Jurgensen, R. Rudick, J Feitcher, F. Munschauer, M. Panzara, and B Weinstock-Guttman Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire Multiple Sclerosis, August 1, 2008; 14(7): 940 - 946. [Abstract] [PDF] |
||||
![]() |
O. Ghaffar and A. Feinstein Multiple sclerosis and cannabis: A cognitive and psychiatric study Neurology, July 15, 2008; 71(3): 164 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF] |
||||
![]() |
M. Summers, L. Fisniku, V. Anderson, D. Miller, L. Cipolotti, and M. Ron Cognitive impairment in relapsing--remitting multiple sclerosis can be predicted by imaging performed several years earlier Multiple Sclerosis, March 1, 2008; 14(2): 197 - 204. [Abstract] [PDF] |
||||
![]() |
R. Zivadinov, B. Weinstock-Guttman, R. Benedict, M. Tamano-Blanco, S. Hussein, N. Abdelrahman, J. Durfee, and M. Ramanathan Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor Hum. Mol. Genet., November 15, 2007; 16(22): 2659 - 2668. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Houtchens, R.H.B. Benedict, R. Killiany, J. Sharma, Z. Jaisani, B. Singh, B. Weinstock-Guttman, C. R.G. Guttmann, and R. Bakshi Thalamic atrophy and cognition in multiple sclerosis Neurology, September 18, 2007; 69(12): 1213 - 1223. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Younes, J. Hill, J. Quinless, M. Kilduff, B. Peng, S. Cook, and D. Cadavid Internet-based cognitive testing in multiple sclerosis Multiple Sclerosis, September 1, 2007; 13(8): 1011 - 1019. [Abstract] [PDF] |
||||
![]() |
R. H.B. Benedict, J. Bruce, M. G. Dwyer, B. Weinstock-Guttman, C. Tjoa, E. Tavazzi, F. E. Munschauer, and R. Zivadinov Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis Multiple Sclerosis, July 1, 2007; 13(6): 722 - 730. [Abstract] [PDF] |
||||
![]() |
B A Parmenter, B Weinstock-Guttman, N Garg, F Munschauer, and R H. Benedict Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test Multiple Sclerosis, January 1, 2007; 13(1): 52 - 57. [Abstract] [PDF] |
||||
![]() |
L. Bo, J. J. G. Geurts, P. van der Valk, C. Polman, and F. Barkhof Lack of Correlation Between Cortical Demyelination and White Matter Pathologic Changes in Multiple Sclerosis Arch Neurol, January 1, 2007; 64(1): 76 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. B. Benedict, J. M. Bruce, M. G. Dwyer, N. Abdelrahman, S. Hussein, B. Weinstock-Guttman, N. Garg, F. Munschauer, and R. Zivadinov Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol, September 1, 2006; 63(9): 1301 - 1306. [Abstract] [Full Text] [PDF] |
||||
![]() |
H Hildebrandt, H K Hahn, J A Kraus, A Schulte-Herbruggen, B Schwarze, and G Schwendemann Memory performance in multiple sclerosis patients correlates with central brain atrophy Multiple Sclerosis, August 1, 2006; 12(4): 428 - 436. [Abstract] [PDF] |
||||
![]() |
S D Brass, R H. Benedict, B Weinstock-Guttman, F Munschauer, and R Bakshi Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis Multiple Sclerosis, August 1, 2006; 12(4): 437 - 444. [Abstract] [PDF] |
||||
![]() |
J Sepulcre, S Vanotti, R Hernandez, G Sandoval, F Caceres, O Garcea, and P Villoslada Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test Multiple Sclerosis, April 1, 2006; 12(2): 187 - 195. [Abstract] [PDF] |
||||
![]() |
H. K. Mathiesen, A. Jonsson, T. Tscherning, L. G. Hanson, J. Andresen, M. Blinkenberg, O. B. Paulson, and P. S. Sorensen Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. Arch Neurol, April 1, 2006; 63(4): 533 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Pomeroy, P. M. Matthews, J. A. Frank, E. K. Jordan, and M. M. Esiri Demyelinated neocortical lesions in marmoset autoimmune encephalomyelitis mimic those in multiple sclerosis Brain, November 1, 2005; 128(11): 2713 - 2721. [Abstract] [Full Text] [PDF] |
||||
![]() |
R H. Lazeron, J B Boringa, M Schouten, B M. Uitdehaag, E Bergers, J Lindeboom, M J Eikelenboom, P H Scheltens, F Barkhof, and C H Polman Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis Multiple Sclerosis, October 1, 2005; 11(5): 524 - 531. [Abstract] [PDF] |
||||
![]() |
R. A. Bermel, S. R. Puli, R. A. Rudick, B. Weinstock-Guttman, E. Fisher, F. E. Munschauer III, and R. Bakshi Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity Arch Neurol, September 1, 2005; 62(9): 1371 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. B. Benedict, R. Zivadinov, D. A. Carone, B. Weinstock-Guttman, J. Gaines, C. Maggiore, J. Sharma, M.-A. Tomassi, and R. Bakshi Regional Lobar Atrophy Predicts Memory Impairment in Multiple Sclerosis AJNR Am. J. Neuroradiol., August 1, 2005; 26(7): 1824 - 1831. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. G. Geurts, L. Bo, P. J. W. Pouwels, J. A. Castelijns, C. H. Polman, and F. Barkhof Cortical Lesions in Multiple Sclerosis: Combined Postmortem MR Imaging and Histopathology AJNR Am. J. Neuroradiol., March 1, 2005; 26(3): 572 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bakshi, G. J. Hutton, J. R. Miller, and E.-W. Radue The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis Neurology, December 14, 2004; 63(11_suppl_5): S3 - S11. [Abstract] [Full Text] |
||||
![]() |
D. Cox, D. Pelletier, C. Genain, S. Majumdar, Y. Lu, S. Nelson, and D. C Mohr The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients Multiple Sclerosis, December 1, 2004; 10(6): 626 - 629. [Abstract] [PDF] |
||||
![]() |
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology, November 9, 2004; 63(9): 1579 - 1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Amato, M. L. Bartolozzi, V. Zipoli, E. Portaccio, M. Mortilla, L. Guidi, G. Siracusa, S. Sorbi, A. Federico, and N. De Stefano Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment Neurology, July 13, 2004; 63(1): 89 - 93. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |